EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm

2024-06-28, 10.15 (CEST)

Regulatory

EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm’s listing committee has approved that the Company’s shares are admitted to trading on Nasdaq Stockholm Main Market. The prospectus that has been prepared in connection with the list change has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on EQL Pharma’s website, www.eqlpharma.com, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

A listing of the Company’s shares on Nasdaq Stockholm is an important step in EQL Pharma’s continued development and gives the Company further access to the Swedish and international capital markets. EQL Pharma has been listed on Spotlight Stock Market since 2013, but the board of directors believes that the listing of the Company’s share on Nasdaq Stockholm will increase the conditions for broadening EQL Pharma’s shareholder base and give the Company access to additional international and institutional investors, which is deemed to promote the Company’s continued development. Furthermore, the listing also carries a quality stamp for EQL Pharma and its operations.

EQL Pharma’s shares will be traded in the Small Cap segment under the ticker EQL and ISIN code SE0005497732. There will be no offering to subscribe for or otherwise acquire new shares in connection with the list change. Shareholders in EQL Pharma do not need to take any actions. The first day of trading on Nasdaq Stockholm Main Market is Thursday 4 July 2024 and the last day of trading on Spotlight Stock Market is Wednesday 3 July 2024.

Advisors

Setterwalls Advokatbyrå AB is acting as legal advisor to EQL Pharma in connection with the listing.

Press Release 2024-06-28 EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.